Injectable compositions of single bilayer vesicles encapsulating enfumafungin derived triterpenoid antifungal compounds can be administered intravenously to treat or prevent fungal infections, while having reduced local injection site reactions (ISRs). The enfumafungin derived triterpenoid antifungal compounds are inhibitors of (1,3)-ß-D-glucan synthesis and are useful in the treatment or prevention of fungal infections, such as systemic fungal infections, including those caused by Candida and Aspergillus species.
